ALT, Alanine Aminotransferase; APO C3, Apolipoprotein C3; ARFI, Acoustic Radiation Forced Impulse; AST, Aspartate Aminotransferase; ATPIII, Adult Treatment Panel III; BMI, Body mass index; CAD, Coronary artery disease; CC, Cryptogenic Cirrhosis; CIMT, Carotid Intima Media Thickness; CK 18, Cytokeratin 18; CT, Computed Tomography; DM, Diabetes Mellitus; EBP, Enhancer-Binding Protein; EMA, Anti-Endomysial antibodies; FFA, Free Fatty Acids; FMD, Flow-Mediated Vasodilatation; FPG, Fasting Plasma Glucose; GTT, Glucose Tolerance Test; HCC, Hepatocellular Carcinoma; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; HTG, Hepatic triglyceride; HTN, Hypertension; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose Tolerance; IKK-ß, Inhibitor of nuclear factor kappa-B kinase beta; IR, Insulin resistance; IRS-1, Insulin Receptor Substrate-1; ITT, Insulin Tolerance Test; LFTs, Liver Function Tests; MRE, Magnetic Resonance Elastography; MS, Metabolic syndrome; NAFLD; NAFLD, Non-alcoholic fatty liver disease; NASH; NASH, Non-Alcoholic Steatohepatitis; NF-κß, Nuclear Factor Kappa Β; PCOS, Polycystic Ovarian Syndrome; PPG, Post-Prandial Glucose; PROCAM, Prospective Cardiovascular Munster study; SREBP, Sterol-Regulatory Element-Binding Protein; T2DM, Type 2 Diabetes Mellitus; TE, Transient elastography; TG, Triglycerides; TTG, Anti-tissue transglutaminase; VHCC, Virus-related HCC; VLDL, Very Low Density Lipoprotein; WHO, World Health Organization; cryptogenic cirrhosis; insulin resistance; nonalcoholic steatohepatitis